Defence Therapeutics Inc. (DTC) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Defence Therapeutics Inc. (DTC) has a cash flow conversion efficiency ratio of 1.144x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-1.40 Million ≈ $-1.64 Million USD) by net assets (€-1.22 Million ≈ $-1.43 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See DTC equity to assets ratio to measure how much of total assets are equity-financed.
Defence Therapeutics Inc. - Cash Flow Conversion Efficiency Trend (2020–2024)
This chart illustrates how Defence Therapeutics Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Check total reinvestment intensity of Defence Therapeutics Inc. to assess the company's total reinvestment commitment from operating cash flow.
Defence Therapeutics Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Defence Therapeutics Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Pointerra Ltd
AU:3DP
|
2.015x |
|
Primega Group Holdings Limited Ordinary Shares
NASDAQ:PGHL
|
N/A |
|
CCID Consulting Company Limited
F:CCX
|
N/A |
|
Trimegah Karya Pratama Tbk PT
JK:UVCR
|
0.798x |
|
Dubber Corporation Ltd
AU:DUB
|
-0.685x |
|
Samyang Holdings Corp
KO:000075
|
0.036x |
|
Maniker F & G Co. Ltd
KQ:195500
|
0.025x |
|
Yorbeau Resources Inc
TO:YRB
|
-0.014x |
Annual Cash Flow Conversion Efficiency for Defence Therapeutics Inc. (2020–2024)
The table below shows the annual cash flow conversion efficiency of Defence Therapeutics Inc. from 2020 to 2024. For the full company profile with market capitalisation and key ratios, see DTC company net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-06-30 | €-3.58 Million ≈ $-4.19 Million |
€-4.29 Million ≈ $-5.01 Million |
1.196x | +124.47% |
| 2023-06-30 | €1.57 Million ≈ $1.83 Million |
€-7.66 Million ≈ $-8.95 Million |
-4.889x | -131.35% |
| 2022-06-30 | €-387.56K ≈ $-453.10K |
€-6.04 Million ≈ $-7.07 Million |
15.596x | +3837.50% |
| 2021-06-30 | €5.49 Million ≈ $6.41 Million |
€-2.29 Million ≈ $-2.68 Million |
-0.417x | -485.46% |
| 2020-06-30 | €1.86 Million ≈ $2.18 Million |
€-132.83K ≈ $-155.29K |
-0.071x | -- |
About Defence Therapeutics Inc.
Defence Therapeutics Inc. develops a biological drug enhancer platform that improves the efficacy and safety of a multitude of a multitude of biological/biosimilar-based pharmaceuticals used in the treatment of cancer and infectious diseases. The company focuses on the research, development, and advancement of products using its Accum technology, including antibody drug conjugates targeting vario… Read more